Bio-Rad Laboratories, Inc. (BIO) Balance Sheet

Total assets have risen from $9.4B to $10.8B over the same period while total liabilities have stayed near $3B, which suggests the asset growth is concentrated in equity-accounted and fair-valued holdings. Retained earnings climbing from $7.4B to $8.5B likely reflects the volatile non-operating gains flowing through net income, so investors should monitor whether this base remains stable if Sartorius valuations reverse.

A D/E ratio near 0.2 is low for a diagnostics and life science company, which appears to give management meaningful flexibility regardless of operating conditions. Because debt has not declined meaningfully despite cash flow of roughly $1.2B cumulative over the period, the company appears to be holding debt as a standing structure rather than actively deleveraging, which warrants further investigation into its refinancing plans.

The decline in current ratio appears to reflect a shift in working capital composition and a normalization of short-term assets rather than a deterioration in ability to meet obligations, since a ratio above 3 remains comfortable. Cash of roughly $465M at Q3 2026 provides a buffer, but with operating cash flow only around $96M per quarter, the company's liquidity appears dependent on sustained operating cash generation rather than cash reserves alone.

Falling PP&E alongside rising total assets points to the balance sheet growing through financial holdings and fair-valued investments rather than the operating base, which may limit the earnings power of the core business. Goodwill stability suggests no recent impairment charge, but the company's asset mix leans toward non-operating value, which investors should weigh against the operating margins near 10%.